In an earlier article, I documented how George Yancopoulos, the co-founder and Chief Scientific Officer of Regeneron Pharmaceuticals, other Regeneron researchers and Yale University researchers humanized mice with human fetal liver obtained from Advanced Biosciences Resources in two different studies, in 2011 and in 2017.
I have since found a third 17 March 2021 study conducted by Yale University researchers in cooperation with Regeneron Pharmaceuticals in which mice humanized with human fetal liver were infected with a SARS-COV2 infection. After successfully exhibiting human COVID-19 pathology, the mice were treated with human monoclonal antibodies with some degree of efficacy.
In the Introduction of the study, "A humanized mouse model of chronic COVID-19 to evaluate disease mechanisms and treatment options," (Sefik et al.), Yale University researchers state their objective of developing a humanized mouse platform which can be used to model SARS-CoV-2 infection in living human tissue.
From the Introduction:
Mice with a human immune system (humanized mice) serve as invaluable tools to study the development and function of the human immune system in vivo.
They elaborate further:
By adapting recombinant adeno-associated virus (AAV)-driven gene therapy to deliver human ACE2 to the lungs18, which allows infection with SARS-CoV-2 of MISTRG6 mice engrafted with a human hematopoietic stem and progenitor cells, we created a humanized mouse model of COVID19 that recapitulates the distribution and function of the human innate and adaptive immune system and is amenable to the mechanistic study of COVID 19 and its myriad of complications 12,19
The team of researchers proposed to engineer a humanized mouse model by engrafting human hematopoietic stem and progenitor cells without the need for complex surgical implantation of human fetal liver and thymus on the mouse:
We conclude that human IL-6 knock-in mice represent a novel and improved model for human adaptive immunity without relying on complex surgery to transplant human fetal thymus and liver. These mice can therefore be used to exploit or evaluate immunization regimes that would be unethical or untenable in humans.
A look at the Methods and Materials section reveals their method of extracting CD34+ cells from human fetal liver and injecting into the livers of the mice.
The researchers concluded that their MISTRG6-hACE2 humanized mice can be infected with SARS-CoV-2 and present with characteristic signs of human COVID-19 lung pathology after infection.
They administered human monoclonal antibody treatments (mAbs) to the mice, and they discovered that it was efficacious in controlling viral infection.
Their conclusion:
Our humanized model of COVID-19 could be particularly useful in evaluating efficacy and timing for these antibodies. When administered in a timely manner mAbs could be particularly useful in protecting uninfected individuals and preventing transmission from an infected person by rapid clearance of infectious virus.
At this point it must be noted that the Yale researchers were working in a Regeneron Pharmaceuticals laboratory and were working under a Yale-Regeneron material transfer agreement as shown in this screenshot from the Materials and Methods section:
This is significant because Regeneron is famous for its COVID monoclonal antibody treatment, REGN-COV2, which Trump allegedly took when he stricken with COVID and was hospitalized at Walter Reed Hospital in October, 2020. Trump called the Regeneron a "miracle cure" and vowed to make it available to all Americans at no cost.
It would appear that the Yale-Regeneron MSTRG6-hACE2 mice with human immune systems constructed with human fetal liver were developed in collaboration with Regeneron Pharmaceuticals specifically for the testing of monoclonal antibody treatments on COVID-19-infected humanized mice.
As I have discussed in a previous article, Dr. Tara Sander Lee of the pro-life Charlotte Lozier stated on Twitter that no human fetal tissue was used to make the Regeneron monoclonal antibody cocktail---a claim that was thoroughly debunked by Professor Gerard S. Harbison of the University of Nebraaka and by Regeneron's own statements. To my knowledge, she has never addressed the issue of Regeneron possibly using mice humanized with human fetal organs to test the efficacy of monoclonal antibody therapy I have contacted her to see if she has any comment on this Yale-Regeneron study but have received no reply.
The fact remains, as definitively shown in this Yale-Regneron study, MSTRG6-hACE2 mice (humanized with human fetal liver) appear to be the specially designed test mouse model for Regeneron's COVID-19 monoclonal antibody treatments.
See this article for information on Regeneron's 2011 and 2017 studies using aborted baby organs:
See this article for information on the dubious ingredients in the Regeneron monoclonal antibody cocktail:
See this article for information on the use of the HEK293 embryonic stem cell in the Regeneron monoclonal antibody cocktail:
Comments